Dataset Information

Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer.

ABSTRACT:

Background

Estrogen metabolite concentrations of 2-hydroxyestrone (2-OHE₁) and 16-hydroxyestrone (16-OHE₁) may be associated with breast carcinogenesis. However, no study has investigated their possible impact on mortality after breast cancer.

Methods

This population-based study was initiated in 1996-1997 with spot urine samples obtained shortly after diagnosis (mean?=?96?days) from 683 women newly diagnosed with first primary breast cancer and 434 age-matched women without breast cancer. We measured urinary concentrations of 2-OHE₁ and 16-OHE₁ using an enzyme-linked immunoassay. Vital status was determined via the National Death Index (n?=?244 deaths after a median of 17.7?years of follow-up). We used multivariable-adjusted Cox proportional hazards to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the estrogen metabolites-mortality association. We evaluated effect modification using likelihood ratio tests. All statistical tests were two-sided.

Results

Urinary concentrations of the 2-OHE₁ to 16-OHE₁ ratio (>median of 1.8 vs ?median) were inversely associated with all-cause mortality (HR?=?0.74, 95% CI?=?0.56 to 0.98) among women with breast cancer. Reduced hazard was also observed for breast cancer mortality (HR?=?0.73, 95% CI?=?0.45 to 1.17) and cardiovascular diseases mortality (HR?=?0.76, 95% CI?=?0.47 to 1.23), although the 95% confidence intervals included the null. Similar findings were also observed for women without breast cancer. The association with all-cause mortality was more pronounced among breast cancer participants who began chemotherapy before urine collection (n?=?118, HR?=?0.42, 95% CI?=?0.22 to 0.81) than among those who had not (n?=?559, HR?=?0.98, 95% CI?=?0.72 to 1.34; P _interaction = .008).

Conclusions

The urinary 2-OHE₁ to 16-OHE₁ ratio may be inversely associated with long-term all-cause mortality, which may depend on cancer treatment status at the time of urine collection.

SUBMITTER: Wang T

PROVIDER: S-EPMC7236781 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer.

Wang Tengteng T Nichols Hazel B HB Nyante Sarah J SJ Bradshaw Patrick T PT Moorman Patricia G PG Kabat Geoffrey C GC Parada Humberto H Khankari Nikhil K NK Teitelbaum Susan L SL Terry Mary Beth MB Santella Regina M RM Neugut Alfred I AI Gammon Marilie D MD

JNCI cancer spectrum 20200302 3

<h4>Background</h4>Estrogen metabolite concentrations of 2-hydroxyestrone (2-OHE<sub>1</sub>) and 16-hydroxyestrone (16-OHE<sub>1</sub>) may be associated with breast carcinogenesis. However, no study has investigated their possible impact on mortality after breast cancer.<h4>Methods</h4>This population-based study was initiated in 1996-1997 with spot urine samples obtained shortly after diagnosis (mean = 96 days) from 683 women newly diagnosed with first primary breast cancer and 434 age-matche ...[more]

PMID: 32455334

Similar Datasets

Project description:Endogenous estrogens and estrogen metabolism are hypothesized to be associated with premenopausal breast cancer risk but evidence is limited. We examined 15 urinary estrogens/estrogen metabolites and breast cancer risk among premenopausal women in a case-control study nested within the Nurses' Health Study II (NHSII). From 1996 to 1999, urine was collected from 18,521 women during the mid-luteal menstrual phase. Breast cancer cases (N = 247) diagnosed between collection and June 2005 were matched to two controls each (N = 485). Urinary estrogen metabolites were measured by liquid chromatography-tandem mass spectrometry and adjusted for creatinine level. Relative risks (RR) and 95% confidence intervals (CI) were estimated by multivariate conditional logistic regression. Higher urinary estrone and estradiol levels were strongly significantly associated with lower risk (top vs. bottom quartile RR: estrone = 0.52; 95% CI, 0.30-0.88; estradiol = 0.51; 95% CI, 0.30-0.86). Generally inverse, although nonsignificant, patterns also were observed with 2- and 4-hydroxylation pathway estrogen metabolites. Inverse associations generally were not observed with 16-pathway estrogen metabolites and a significant positive association was observed with 17-epiestriol (top vs. bottom quartile RR = 1.74; 95% CI, 1.08-2.81; P(trend) = 0.01). In addition, there was a significant increased risk with higher 16-pathway/parent estrogen metabolite ratio (comparable RR = 1.61; 95% CI, 0.99-2.62; P(trend) = 0.04). Other pathway ratios were not significantly associated with risk except parent estrogen metabolites/non-parent estrogen metabolites (comparable RR = 0.58; 95% CI, 0.35-0.96; P(trend) = 0.03). These data suggest that most mid-luteal urinary estrogen metabolite concentrations are not positively associated with breast cancer risk among premenopausal women. The inverse associations with parent estrogen metabolites and the parent estrogen metabolite/non-parent estrogen metabolite ratio suggest that women with higher urinary excretion of parent estrogens are at lower risk.

Project description:BackgroundEnvironmental phenols, compounds used widely in personal care and consumer products, are known endocrine disruptors. Few epidemiologic studies have examined the association of phenol biomarkers with breast cancer incidence and, to our knowledge, none have considered associations with mortality following breast cancer. We examined seven urinary phenol biomarkers in association with breast cancer incidence and subsequent mortality, and examined effect measure modification by body mass index (BMI).MethodsParticipants included 711 women with breast cancer and 598 women without breast cancer who were interviewed for the population-based Long Island Breast Cancer Study Project. Among women with breast cancer, phenol biomarkers were quantified in spot urine samples collected on average within three months of a first diagnosis of primary in situ or invasive breast cancer in 1996-1997. Women with breast cancer were monitored for vital status using the National Death Index. After a median follow-up of 17.6 years, we identified 271 deaths, including 98 deaths from breast cancer. We examined creatinine-corrected phenol concentrations and the sum of parabens (Σparabens) in association with breast cancer incidence using logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs), and with mortality using Cox regression to estimate hazard ratios (HRs) and 95% CIs. We evaluated multiplicative effect measure modification using cross-product terms in nested models.ResultsThe highest (vs lowest) quintiles of urinary methylparaben, propylparaben, and Σparabens were associated with risk of breast cancer with ORs ranging from 1.31 to 1.50. Methylparaben, propylparaben, and Σparabens were also associated with all-cause mortality HRs ranging from 0.68 to 0.77. Associations for breast cancer incidence were more pronounced among women with BMI < 25.0 kg/m2 than among women with BMI ≥ 25.0 kg/m2; however, associations for mortality were more pronounced among women with BMI ≥ 25 kg/m2 than among women with BMI < 25 kg/m2.ConclusionsSelect parabens may have differential associations with risk of developing breast cancer and mortality following breast cancer.

Project description:BackgroundPhthalates, known endocrine disruptors, may play a role in breast carcinogenesis. Few studies have examined phthalates in relation to breast cancer (BC), and, to our knowledge, none have considered survival following BC.ObjectivesWe examined 11 urinary phthalate metabolites, individually and as molar sum groupings, in association with BC incidence and subsequent survival.MethodsOur study includes 710 women diagnosed with first primary BC in 1996-1997 and 598 women without BC from Long Island, New York. Within 3 mo of diagnosis, participants provided spot urine samples. Nine phthalate metabolites were measured in all women; two [monocarboxyoctyl phthalate (MCOP) and monocarboxy-isononyl phthalate (MCNP)] were measured in 320 women with and 205 without BC. Women with BC were followed since diagnosis using the National Death Index; during follow-up (median=17.6 y), we identified 271 deaths (98 BC related). We examined creatinine-corrected metabolite concentrations in association with: BC, using logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) and all-cause/BC-specific mortality, using Cox regression to estimate hazard ratios (HRs) and 95% CIs. We also examined effect modification by body mass index (BMI) and estrogen receptor (ER) status.ResultsThe highest (vs. lowest) quintiles of mono(3-carboxypropyl) phthalate (MCPP), monobenzyl phthalate (MBzP), MCNP, and MCOP were associated with BC ORs ranging from 0.71-0.73. The highest (vs. lowest) quintiles of mono(2-ethylhexyl) phthalate (MEHP) and MCOP were associated with BC-specific mortality HRs of 0.54 (95% CI: 0.28, 1.04) and 0.55 (95% CI: 0.23, 1.35), respectively. For BC-specific mortality, interactions were significant between BMI and mono(2-ethyl-5-oxyhexyl) phthalate (MEOHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), with positive associations among women with BMI<25 and inverse associations among women with BMI≥25.0 kg/m2.ConclusionsConsistent with laboratory evidence, we observed inverse associations between urinary concentrations of several phthalate metabolites and BC and subsequent survival; however, these results should be interpreted with caution given that biospecimen collection among women with BC occurred after diagnosis, which may be of particular concern for our case-control findings. https://doi.org/10.1289/EHP2083.

Dataset Information

Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer.

Background

Methods

Results

Conclusions

Publications

Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets